

# Versican Plus DHP lyophilisate and solvent for suspension for injection for dogs

Authorised

- Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
- Canine adenovirus 2, strain CAV-2-Bio 13, Live
- Canine distemper virus, strain CDV Bio 11/A, Live

## Product identification

**Medicine name:**

Versican Plus DHP lyophilisate and solvent for suspension for injection for dogs

---

**Active substance:**

Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live

Canine adenovirus 2, strain CAV-2-Bio 13, Live

Canine distemper virus, strain CDV Bio 11/A, Live

---

**Target species:**

Dog

---

**Route of administration:**

Subcutaneous use

---

## Product details

**Active substance and strength:**

Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live  
19953.00 50% tissue culture infectious dose / 1.00 Dose

Canine adenovirus 2, strain CAV-2-Bio 13, Live  
3981.00 50% tissue culture infectious dose / 1.00 Dose

Canine distemper virus, strain CDV Bio 11/A, Live  
1259.00 50% tissue culture infectious dose / 1.00 Dose

---

**Pharmaceutical form:**

Lyophilisate and solvent for suspension for injection

---

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**

QI07AD02

---

**Legal status of supply:**

Veterinary medicinal product subject to veterinary prescription

---

**Authorisation status:**

Valid

---

**Authorised in:**

Germany

---

**Available in:**

Germany

---

**Package description:**

(ID2): 1 Box with (50 Vial (Glass) with 1 Dose and 50 Vial (Glass) with 1 ml) (50.0 Dose, 50.0 ml)

(ID1): 1 Box with (25 Vial (Glass) with 1 Dose and 25 Vial (Glass) with 1 ml) (25.0 Dose, 25.0 ml)

---

## Additional information

**Entitlement type:**

Marketing Authorisation

---

**Legal basis of product authorisation:**

Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

---

**Marketing authorisation holder:**

Zoetis Deutschland GmbH

---

**Marketing authorisation date:**

4/04/2016

---

**Manufacturing sites for batch release:**

Bioveta a.s.

---

**Responsible authority:**

Paul-Ehrlich-Institut

---

**Authorisation number:**

PEI.V.11783.01.1

---

**Date of authorisation status change:**

15/02/2021

---

**Reference member state:**

Germany

---

**Procedure number:**

DE/V/0267/001

---

**Concerned member states:**

Belgium Bulgaria Cyprus Denmark Finland Greece Hungary Italy  
Luxembourg Netherlands Norway Poland Portugal Spain Sweden  
United Kingdom (Northern Ireland)

---

To consult adverse reactions on veterinary medicinal products please go to  
[www.adrreports.eu/vet](http://www.adrreports.eu/vet)

## Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.

2613563-paren-20251101.pdf

2613563-paren-20170427.pdf.pdf